Athersys, Inc. (ATHX)
(Delayed Data from NSDQ)
$1.55 USD
+0.04 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.55 USD
+0.04 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
by Zacks Equity Research
Investors in Athersys, Inc. (ATHX) need to pay close attention to the stock based on moves in the options market lately.
Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
by Zacks Equity Research
Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.
Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
by Zacks Equity Research
At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.
Ironwood, Allergan Report Positive Linzess IBS-C Study Data
by Zacks Equity Research
Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
by Zacks Equity Research
Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.
Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
by Zacks Equity Research
Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.
Celgene (CELG) Otezla Approved in Japan for Two Indications
by Zacks Equity Research
Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.
Roche Presents Positive Follicular Lymphoma Data on Gazvya
by Zacks Equity Research
Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
by Zacks Equity Research
Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
by Zacks Equity Research
Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101
Foamix Completes Enrolment in Phase III Acne Drug Studies
by Zacks Equity Research
Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies
New Strong Buy Stocks for November 14th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday